Search research articles
Contact Us
Filters
Showing results (281-290 of 332) with videos related to
Page
of 34
Sort By:
The New England Journal of Medicine
|
March 31, 2018
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Mojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, et al.
Swiss Medical Weekly
|
March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood
|
February 2, 2022
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
Tim Grob, Adil S A Al Hinai, Mathijs A Sanders, et al.
Leukemia
|
February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Bone Marrow Transplantation
|
January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
Meral Beksac, Diderik-Jan Eikema, Linda Koster, et al.
Blood Cancer Journal
|
June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis
Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Hemasphere
|
August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis
Markus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Frontiers in Neurology
|
August 1, 2022
Absence of Susceptibility Vessel Sign in Patients With Malignancy-Related Acute Ischemic Stroke Treated With Mechanical Thrombectomy
Morin Beyeler, Nebiyat F Belachew, Moritz Kielkopf, et al.
Leukemia
|
October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Michael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Hemasphere
|
January 17, 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, et al.
Page
of 34
Search research articles
Search
Showing results (281-290 of 332) with videos related to
Sort By:
Page
of 34
The New England Journal of Medicine
|
March 31, 2018
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Mojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, et al.
Swiss Medical Weekly
|
March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016
Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood
|
February 2, 2022
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
Tim Grob, Adil S A Al Hinai, Mathijs A Sanders, et al.
Leukemia
|
February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Bone Marrow Transplantation
|
January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
Meral Beksac, Diderik-Jan Eikema, Linda Koster, et al.
Blood Cancer Journal
|
June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis
Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Hemasphere
|
August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis
Markus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Frontiers in Neurology
|
August 1, 2022
Absence of Susceptibility Vessel Sign in Patients With Malignancy-Related Acute Ischemic Stroke Treated With Mechanical Thrombectomy
Morin Beyeler, Nebiyat F Belachew, Moritz Kielkopf, et al.
Leukemia
|
October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Michael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Hemasphere
|
January 17, 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, et al.
Page
of 34